TABLE 3.

Effect of civamide treatment during primary infection on recurrent genital herpes

Group	Treatmenta	n	No. with recurrences	No. of days recurrences observed between indicated days p.i.b
				15–63	64–77	78–91
1	BID for 10 days	13	8c	3.1 ± 5.0d	0.4 ± 0.8e	0.5 ± 1.0
2	QD for 10 days	13	12	4.4 ± 4.2c	0.2 ± 0.4c	0.6 ± 0.8
3	QD for 5 days	15	14	3.1 ± 2.5d	0.9 ± 1.1	1.1 ± 1.8
4	QD for 3 days	15	14	4.5 ± 4.5c	0.4 ± 0.7e	0.3 ± 0.6
5	QD for 1 day	13	12	5.5 ± 3.3e	0.9 ± 1.0	0.5 ± 0.7
6	None	20	20	9.8 ± 4.0	1.5 ± 1.4	0.8 ± 1.2

^aIntravaginal and topical 1.25% civamide beginning 24 h after intravaginal HSV-2 inoculation. BID, twice daily; QD, once a day. 

^bMean ± standard deviation. 

^cP < 0.01 versus group 6. 

^dP < 0.001 versus group 6. 

^eP < 0.05 versus group 6.